Adding Pentoxifylline to Psoriasis Treatment
Treatments studied
Part of Skin clinical trials.
This trial tests whether adding pentoxifylline (a medication that improves blood flow) to your current psoriasis cream treatment helps reduce psoriasis patches. You'll be on stable topical therapy for at least 2 weeks, then the study will see if the added medication improves your skin.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–65 years old
- Mild-to-moderate plaque psoriasis (affecting 3–10% of your skin or a PASI score of 3–10)
- Already using a stable topical psoriasis cream for at least 2 weeks before starting
- Able to attend scheduled study visits and follow the study plan
- Not pregnant or breastfeeding
- No severe liver or kidney disease, significant bleeding problems, or allergies to pentoxifylline
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication, CBP-0276, to see if it improves psoriasis symptoms and quality of life. It is for people with moderate to severe plaque psoriasis who might need stronger treatment.
This trial tests an oral medication called HS-10374 for people with mild to moderate plaque psoriasis who haven't gotten enough relief from topical treatments. The study will check if the drug is safe and effective at clearing psoriasis patches.
This trial tests a new medication called HSK44459 for people with moderate to severe plaque psoriasis who need systemic therapy (medicine that works throughout the body). The goal is to see if it is safe and effective.
This trial tests whether adding the medicine pentoxifylline to standard care can help people with ulcerative colitis. It’s designed to see if this combination improves symptoms by changing inflammation.
This study tests if pentoxifylline, a medicine typically used for circulation, can help reduce joint inflammation in people with rheumatoid arthritis who still have active symptoms despite taking standard DMARDs.
This study tests whether adding pentoxifylline to usual care can improve health outcomes in people with Eisenmenger syndrome. It may help reduce problems related to blood flow and vessel function, especially for those not recently hospitalized.
Hear when a new Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.